Alembic Global Holding SA

Alembic Global Holding SA (AGH) is a Swiss holding company based at Rue Fritz-Courvoisier 40, La Chaux-de-Fonds, Switzerland. It is the wholly owned subsidiary of Alembic Pharmaceuticals Limited (NSE: APLLTD; BSE: 533573), a publicly listed Indian pharmaceutical manufacturer headquartered in Vadodara, Gujarat. AGH serves as the holding/parent entity for the group's overseas businesses, including Alembic Pharmaceuticals Inc. (New Jersey) and other units across the US, Europe, UAE and Australia. It is a subsidiary, not a separate public company, and does not publish standalone headcount or revenue.

Operations. AGH "manufactures and markets pharmaceutical products" and functions as the overseas commercial and regulatory hub for the Alembic group's generics business. Its parent develops and sells Indian branded formulations, international generics and active pharmaceutical ingredients (APIs), with product lines spanning oral solids, injectables, oncology, ophthalmology and dermatology across cardiovascular, anti-infective, cough-and-cold, gastroenterology, diabetic and other therapies. AGH itself appears in US filings as the ANDA applicant — for example, it submitted ANDA No. 212810 for generic melphalan for injection (a version of Evomela), which drew a Paragraph IV suit from Acrotech Biopharma/CyDex. On a consolidated basis the parent group reports roughly 17,000–20,000 employees and trailing-twelve-month revenue of about US$850 million; AGH-level figures were not verifiable.

Litigation posture. AGH is an operating-company defendant, not an NPE. The case data show 1 tracked case as defendant and 0 as plaintiff — the profile of a generic manufacturer targeted in Hatch-Waxman/brand-versus-generic patent suits rather than an entity asserting patents. The single tracked matter sits in the District of New Jersey, a common venue for ANDA litigation because many brand pharmaceutical companies are headquartered there; it is not an Eastern District of Texas case.

Notable case. Celgene Corp. v. Alembic Pharmaceuticals Ltd. et al. (D.N.J.) is the one tracked suit, listing AGH among the Alembic defendants. Reports and related filings describe Celgene's patent infringement actions against Alembic and other generic filers concerning generic versions of Revlimid (lenalidomide) and/or Thalomid (thalidomide). Parallel ANDA litigation has also involved Alembic's melphalan product, reflecting the group's focus on oncology generics.